WILSON JAMES N sold $832K of CORT (indirect holdings)
WILSON JAMES N sold 10,000 indirectly-held shares of CORCEPT THERAPEUTICS INC (CORT) at an average of $83.20 ($82.69–$83.57, $0.83M total) across 2 trades on 2026-06-16 under a Rule 10b5-1 trading plan.
How this was made
The 30-second read
Why it matters
The newest concrete fact is the disclosed sale size ($832,048.95) and execution details (10,000 shares across two trades at ~$82.69–$83.57) filed on 2026-06-18.
Market read
Primarily a sentiment/positioning datapoint; unlikely to change fundamentals given the 10b5-1 pre-arrangement.
What to watch
10b5-1 plans are often routine and can be driven by pre-set liquidity needs or diversification rather than company outlook.
Background
The article is an SEC Form 4 insider transaction disclosure for Corcept Therapeutics (CORT) by director Wilson James N, indicating an open-market sale executed under a pre-arranged 10b5-1 plan.
Ticker impact
Corcept Therapeutics director Wilson James N sold $832,048.95 of CORT via an open-market sale under a pre-arranged 10b5-1 plan on 2026-06-16.
Low likelihood of a sustained price move; any impact is likely limited to short-term sentiment around the filing.
The filing is an SEC Form 4 insider transaction with a stated pre-arranged 10b5-1 plan, which reduces interpretability as new negative information.
Market effects
No sector read-through; this is a single-company insider sale disclosure.
None.
None.
Counterpoint
Because the sale is director-level and sizable, some traders may still interpret it as a mild risk signal despite the 10b5-1 framing.
Key entities
- issuerCorcept Therapeutics Inc
Subject of the Form 4 insider transaction; director Wilson James N sold shares under a 10b5-1 plan.
- insiderWilson James N
Director who executed an open-market sale of 10,000 CORT shares on 2026-06-16.
